Increased Incidence of New-Onset Diabetes Mellitus Type II Following Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell DiseaseDilan A. Patel, Adetola A. Kassim, Josu de la Fuente et al.|Blood|2020Cited by 0
Effective Desensitization Strategy for Patients with Sickle Cell Disease with High Donor Specific Antibodies Undergoing Haploidentical Bone Marrow Transplant with Posttransplant CyclophosphamideEden Biltibo, Josu de la Fuente, Reena Jayani et al.|Blood|2022Cited by 0
The Combination of Rituximab, Plasmapheresis, Intravenous Immunoglobulins and Pre-Transplant Immunosuppression Is an Effective Desensitization Strategy for Patients with Sickle Cell Disease and High Donor Specific Anti-Human Leukocyte Antigen Titer Undergoing Haploidentical Bone Marrow TransplantEden Biltibo, Josu de la Fuente, Katie S. Gatwood et al.|Transplantation and Cellular Therapy|2023Cited by 0